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B I O C H E M I S T R Y
Molecular insights into the surface-catalyzed secondary 
nucleation of amyloid-40 (A40) by the peptide 
fragment A16–22
Samuel J. Bunce1,2*, Yiming Wang3*, Katie L. Stewart2,4, Alison E. Ashcroft2,4,  
Sheena E. Radford2,4†, Carol K. Hall3†, Andrew J. Wilson1,2†
Understanding the structural mechanism by which proteins and peptides aggregate is crucial, given the role of 
fibrillar aggregates in debilitating amyloid diseases and bioinspired materials. Yet, this is a major challenge as the 
assembly involves multiple heterogeneous and transient intermediates. Here, we analyze the co-aggregation of 
A40 and A16–22, two widely studied peptide fragments of A42 implicated in Alzheimer’s disease. We demon-
strate that A16–22 increases the aggregation rate of A40 through a surface-catalyzed secondary nucleation 
mechanism. Discontinuous molecular dynamics simulations allowed aggregation to be tracked from the initial 
random coil monomer to the catalysis of nucleation on the fibril surface. Together, the results provide insight into 
how dynamic interactions between A40 monomers/oligomers on the surface of preformed A16–22 fibrils nucleate 
A40 amyloid assembly. This new understanding may facilitate development of surfaces designed to enhance or 
suppress secondary nucleation and hence to control the rates and products of fibril assembly.
INTRODUCTION
Understanding the molecular mechanisms of peptide self-assembly 
into amyloid fibrils is of key importance in understanding patho-
logical disease states (1) and in designing new functional materials 
(2). Aberrant self-assembly of monomeric peptides or proteins into 
amyloid fibrils is associated with a number of degenerative condi-
tions, notably, Alzheimer’s and Parkinson’s disease (1, 3), in which 
considerable evidence now implicates soluble oligomers as the pri-
mary cause of cellular damage (4, 5). Identifying and characterizing 
the structural changes that occur during peptide assembly into am-
yloid fibrils is essential in the quest to develop strategies to combat 
disease and manufacture bespoke materials (1, 6).
Peptide assembly into amyloid fibrils occurs via a complex nucleation- 
dependent mechanism, in which subtle changes in lowly populated 
states can have marked effects on the rates and products of assembly 
(7). Elegant work has resulted in kinetic models that are able to dissect 
the different contributing steps in assembly, including primary nu-
cleation, elongation, fragmentation, and secondary nucleation (8–11). 
Secondary nucleation is the process whereby transient binding to a 
fibril surface accelerates aggregation by promoting the formation of 
nuclei on the fibril surface. The activation energy barrier for this 
phase of aggregation for A42 has been shown to be enthalpic (11) 
and distinct from that of other kinetic phases of assembly. Secondary 
nucleation is thought to be a specific process in which the effective-
ness of nucleation can depend on the sequence and morphology of 
both the fibril and the assembling monomers, although the “rules” 
defining this specificity have yet to be elucidated. However, eluci-
dating structural insights into these different steps in assembly, including 
the nature of early oligomeric species, is challenging, as circular 
dichroism (CD), infrared, and other spectroscopic techniques gen-
erally only observe population-average data for a whole system. Single- 
molecule Förster resonance energy transfer (FRET) and solid-state 
nuclear magnetic resonance (NMR), which have uncovered clues as 
to the structure of toxic versus nontoxic oligomeric species (12, 13), 
provide information on the average properties of the different spe-
cies at different times. Native ion mobility spectrometry–mass spec-
trometry (IMS-MS) separates ions based on shape as well as mass 
and charge (14) and has been used to provide insights into the pop-
ulation, conformation, and ligand-binding capability of individual 
peptide monomers and oligomers (15). By using photo-induced 
cross-linking (PIC), fleeting interpeptide/intrapeptide interactions 
may be trapped through covalent bond formation (to encode supra-
molecular connectivity) (16). Molecular dynamics (MD) simula-
tions focusing on multipeptide systems at short time scales (<1 ms) 
(17) can help fill the gaps between population-average data and 
individual structures. Such simulations can provide insights into 
self-assembly events in molecular detail, allowing the earliest stages 
of aggregation to be visualized and the course of aggregation to be 
tracked in all-atom detail (18–20).
The amyloid- peptide (A) is a major component of the extra-
cellular plaques observed in Alzheimer’s disease (5, 21). Aggregation 
of A40/42 (Fig. 1A) into amyloid fibrils has been widely studied 
both in vitro and in vivo (22), although numerous questions remain 
about its structure and role in Alzheimer’s disease progression (1, 22). 
Kinetic analysis of the sigmoid growth curves of A40/42 aggregation 
has enabled their assembly mechanisms to be deconvoluted into a 
number of microscopic steps (7, 10). Assembly begins with a lag phase, 
during which time monomers and small amounts of oligomers per-
sist (7). Monomers then undergo a rearrangement step to form a 
nucleus (primary nucleation) from which fibrils can grow. Further 
aggregate growth occurs through pathways that include elongation 
(whereby a monomeric peptide adds onto the end of a growing fibril), 
fragmentation (fibrils break into two smaller aggregates, exponen-
tially increasing growth-competent fibril ends), and surface-catalyzed 
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secondary nucleation (whereby nucleation is catalyzed on the fibril 
surface) (23). Using MD simulations, the energy landscape of A40 
oligomer formation has also been modeled, demonstrating the dif-
ferent kinetic pathways that underlie the formation of prefibrillar 
and nonfibrillar oligomers (17). For A40, primary nucleation has 
been shown to be a slower process than secondary pathways such 
that surface-catalyzed secondary nucleation events dominate the 
growth rate of fibrils (10). Under quiescent conditions, the contri-
bution of fibril fragmentation to the growth of fibrils has been 
shown to be negligible (9). Co-aggregation processes (i.e., where two 
different peptide sequences interact during aggregation but need 
not co-assemble) can result in more complex kinetics due to the 
possibility of the sequences interacting with each other to modulate 
aggregation (24, 25). Such a situation may occur in vivo wherein 
multiple sequences of different lengths of A are formed (26).
Here, we combine fluorescence assays, electrospray ionization 
(ESI)–IMS–MS, and PIC experiments to study the structural mech-
anism of co-assembly of the peptide fragment A16–22 (Fig. 1A), 
which contains the “core recognition motif” KLVFF (27) of A40, 
with the parent A40 sequence. A16–22 has been shown to form fi-
brils with an in-register, antiparallel orientation at neutral pH (28) 
and has been proposed to assemble via an intermediate with out-of- 
register -sheet alignment before reaching the final in-register fibril 
structure (29). The rate of A16–22 aggregation is dependent on pep-
tide concentration and ionic strength (29–31). Discontinuous MD 
(DMD) has also shown that the nucleation-dependent aggregation 
process of A16–22 proceeds from a random coil configuration to 
form multilayer -sheet fibrils, with an in-register antiparallel -sheet 
orientation, in accordance with the experimental data (32). Here 
we show, using fluorescence quenching assays, that A16–22 aggre-
gates more rapidly than A40 and that A16–22 fibril formation then 
increases the aggregation rate of A40 through a surface-catalyzed 
secondary nucleation mechanism, mirroring the behavior observed in 
kinetic analyses of A40/42 aggregation (9, 10) and their co-aggregation 
(24). Using DMD simulations, we also show that the preformed 
A16–22 fibrils increase the early-stage aggregation rate of A40 but 
that the monomeric A16–22 peptides do not, supporting secondary 
nucleation as the mechanism of enhanced A40 aggregation by 
A16–22. These experimentally validated simulations portray the 
structural mechanism of surface-catalyzed nucleation. This new 
understanding may pave the way to the generation of surfaces able 
to enhance or suppress assembly and may inform effective design of 
ligands that modulate therapeutically important amyloid assembly.
RESULTS
A16–22 increases the aggregation rate of A40
To determine whether the presence of A16–22 affects the aggrega-
tion rate of A40, we synthesized or recombinantly expressed the 
peptides (see Materials and Methods, Supplementary Materials, and 
figs. S1 and S2), purified them, and mixed them in different ratios at a 
constant total peptide concentration of 40 M. The rate of aggrega-
tion was then measured using the fluorescence of thioflavin-T 
(ThT; Fig. 1B, Materials and Methods, and fig. S3). Initial experi-
ments showed the expected sigmoid increase in ThT fluorescence 
for A40 (7, 10, 33), indicating the assembly of this peptide into am-
yloid fibrils (Fig. 1B). While A16–22 formed fibrils under the condi-
tions used based on transmission electron microscopy (TEM) images 
(Fig. 2F and fig. S4), as expected (16), ThT fluorescence did not in-
crease over 12 hours (Fig. 1B), indicating that the fibrils formed either 
are unable to bind ThT or do not enhance its fluorescence when 
bound; rotational immobilization of ThT is required for its fluorescent 
Fig. 1. Co-aggregation of A16–22 and A40 results in accelerated aggregation kinetics for A40. (A) Primary sequence of A16–22 and A40, including the groups at 
each terminus. The central recognition motif KLVFF is highlighted in purple. (B) ThT fluorescence assays showing that the aggregation rate of A40 increases as the ratio 
of A16–22 to A40 is increased (with the total peptide concentration held constant at 40 M). (C) Simulation snapshots of the aggregation of six A40 monomers into a 
-sheet–rich hexamer at an A40 concentration of 5 mM. At the start of the simulation (0 s), all the peptides are in random coils, but as the simulation progresses, they 
aggregate into antiparallel, in-register  sheets (104 s). This oligomer then unfolds, losing some of its -sheet structure (230 s) before a rearrangement in which the 
 sheets rearrange, forming a stable fibril, with each A40 peptide containing three  strands (621 s) engaged in parallel intermolecular hydrogen bonding.
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enhancement when bound to amyloid fibrils (34). Other amyloid 
dyes (NIAD-4, Congo Red, and ANS) were screened against A16–22 
fibrils; however, none produced a signal with which to perform ki-
netic assays. The increase in ThT signal in the peptide mixture thus 
reports on the aggregation rate of A40 and how this is affected by 
the presence of A16–22. The experiments in Fig. 1B show that, at a 
constant peptide concentration of 40 M, as the molar ratio of A16–22 
to A40 is increased, the apparent aggregation rate of A40 also in-
creases. Competition between the increased rate of A40 aggre-
gation as A16–22 concentration increases and the decreased rate of 
aggregation of A40 as its concentration correspondingly decreases 
results in maximal apparent rate enhancement at a 1:1 molar ratio 
of the two peptides (Fig. 1B). We accounted for this effect by measuring, 
in parallel, the t1/2 (the time at which the growth curve reaches 50% 
amplitude) value of aggregation of A40 alone at each concentration 
and comparing the t1/2 values with and without A16–22 added (see 
fig. S3). These data show that the effect saturates as would be ex-
pected for secondary nucleation events involving binding to the 
fibril surface.
To characterize the extent to which A40 aggregation is accelerated 
by the presence of A16–22, we calculated the half-time (t1/2) for each 
peptide mixture and normalized to the half time for the equivalent 
concentration of A40 alone (fig. S3). The results revealed a marked, 
and titratable, effect of the presence of A16–22 on the aggregation 
rate of A40, demonstrating an interaction between the two peptides 
that accelerates the rate of assembly.
A16–22 aggregates more rapidly than A40 and is unaffected 
by the presence of A40
As the assembly kinetics of A16–22 could not be measured using 
any of the amyloid dyes surveyed at the concentrations used here, a 
fluorescence quenching assay was developed to determine whether 
A16–22 aggregates more or less rapidly than A40 (Fig. 2A). Similar 
assays have been previously used to monitor the aggregation rates 
of A40 and A42 (35), with fluorescence quenching reporting on 
labeled monomers coming into mutual proximity as oligomers (or 
fibrils) form. For these assays, A16–22 N-terminally labeled with 
tetramethylrhodamine (TAMRA) was synthesized, including a 
Fig. 2. Aggregation kinetics of A16–22 are unaffected by the presence of A40. (A) Schematic showing the principle behind the fluorescence quenching assay used 
to determine the aggregation rate of A16–22. (B) As self-assembly occurs, the TAMRA-labeled peptides [40 M total peptide containing 5% (w/w) TAMRA-Ahx-A16–22] are 
sequestered into the fibril structure. This brings the fluorophores into proximity, resulting in fluorescence quenching. (C) Aggregation of A16–22 [containing 5% (w/w) 
TAMRA-Ahx-A16–22] and A40 at a 1:1 mol/mol ratio (40 M total peptide concentration). A single transient, which is the median of three replicates measured, is shown. 
(D and E) Sedimentation and separation of the pellet and supernatant of the 1:1 mixed system and analysis of the fractions using ESI-MS after 1 hour indicate that A40 is 
present in the (D) supernatant and in only very small amounts within the (E) pellet. (F) Under these conditions, fibrils of A16–22 are present after 5 min of incubation. Scale 
bars, 500 nm.
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6-aminohexanoic acid linker (Ahx) to limit disruption to the na-
tive fibril structure that might arise due to the bulky fluorophore 
(TAMRA- Ahx-A16–22; Supplementary Materials and figs. S1 and S4). 
When incubated in isolation, a 5% (w/w) TAMRA-Ahx-A16–22:95% 
A16–22 mixture (20 M) resulted in a rapid decrease in fluorescence 
intensity followed by a slower phase that plateaued after 1 hour 
(Fig. 2B). In the presence of A40 [1:1 (mol/mol) ratio, 40 M total 
peptide concentration, and 2% (v/v) dimethyl sulfoxide (DMSO)], 
no difference in the rate of fluorescence decrease was observed, in-
dicating that the presence of A40 has no effect on A16–22 aggrega-
tion (Fig. 2C). Analysis of these samples by negative-stain TEM 
showed the presence of fibrils after only 5 min (Fig. 2F). Sedimenta-
tion of the mixed system by centrifugation after 1 hour demonstrated 
that A40 was present mainly in the supernatant (Fig. 2, D and E). 
These results demonstrate that A16–22 aggregates rapidly to form 
amyloid- like fibrils, while A40 remains soluble as monomers/oligomers. 
Thus, although the rate of A40 aggregation is increased by the presence 
of A16–22, limited or no co-assembly between the two peptides 
into fibrils was observed. By contrast, A16–22 aggregation is unaf-
fected by the presence of A40. A40 fibrils have been shown to 
adopt a parallel in-register structure involving most of the polypep-
tide backbone (21, 36), while A16–22 has been shown to form an 
antiparallel -stranded amyloid structure (28, 29). This structural 
incompatibility could account for the absence of co-assembly because 
such a structure would be less stable compared with homomeric 
assemblies. Furthermore, the more rapid fibril assembly of A16–22 
in comparison to A40 disfavors co-assembly on kinetic grounds.
Monomeric A16–22 can interact with monomeric 
and oligomeric A40 through the self-recognition  
motif KLVFF
To determine whether A16–22 and A40 interact transiently in the 
early stages of assembly, we performed native ESI linked to IMS-MS 
(see Materials and Methods). This soft ionization technique has 
been used to identify and structurally characterize amyloid oligo-
mers that formed from several different proteins and peptides 
(14, 15). Under the conditions used here, ESI-IMS-MS immediately 
following mixing revealed that A40 copopulates a number of oligo-
mers, ranging from monomers to pentamers (Fig. 3B, white, and 
table S1), consistent with previous results (33). When incubated 
with A16–22, heteromolecular oligomers were observed (Fig. 3B, 
light blue), along with homomolecular oligomers of A40 (Fig. 3A, 
white). Notably, A16–22 homomolecular oligomers were not observed. 
The heteromolecular oligomers correspond to multiple A16–22 mono-
mers that bound to either an A40 monomer or dimer (table S1). 
Collision cross-section (CCS) estimations from the ESI-IMS-MS 
analysis of the A40 species in the presence or absence of A16–22 
indicate no discernible difference in the gas-phase cross-section of A40, 
Fig. 3. A16–22 can interact with A40 monomers and dimers. (A) Native ESI-IMS-MS drift-scope images of A40 indicate the presence of multiple oligomeric species of 
A40 (white numbers). (B) When mixed at a 1:1 mol/mol ratio with A16–22 (yellow numbers), a number of heteromeric species are observed (light blue numbers) immedi-
ately following mixing. The oligomer size is given (1, 2, 3, etc.), with the charge state in superscript. (C) DMD simulation showing the percent  sheet formed by A40 during 
aggregation in the absence (black) or presence (red) of A16–22. (D) Energy contact map between one monomer of A16–22 and one of A40 scaled by energy (bar shown 
alongside), showing that residues 17 to 20 (LVFF) and 31 to 34 (IIGL) form the strongest interactions. (E) Co-aggregation can have differing effects on the primary nucle-
ation of each peptide, depending on whether the mixed oligomers formed can progress to form mixed fibrils or are off-pathway and take no further part in the aggrega-
tion reaction. Circles represent monomers and blocks represent fibrils, with A16–22 and A40 in red and blue, respectively. Adapted from (24).
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implying that a conformational change in monomer or oligomer 
structure is unlikely to be the provenance for the A16–22-driven in-
crease in the A40 aggregation rate (fig. S5). Despite attempts to 
capture the interaction experimentally by PIC using a diazirine-labeled 
A16–22 (A*16–22; see the Supplementary Materials for synthesis, 
scheme S1, and fig. S1), the site of interaction could not be verified 
(fig. S6 and table S2) likely due to the low percentage of any het-
erodimers present (as assessed by total ion count, 1.0 ± 0.5%) and 
the lower solution concentration of A16–22 arising as a consequence 
of its rapid aggregation.
To further assess the nature of the interactions between A16–22 
and A40, we performed DMD simulations (see Materials and Methods). 
To evaluate the role of interactions between A40 and A16–22 mono-
mers (covered in this section), it was first necessary to perform 
DMD simulations on the aggregation of A40 alone (Fig. 1C) and 
then a 1:1 mixture of the A16–22 and A40 peptide sequences at 
Cpeptide = 5 mM (Fig. 3C). These co-aggregation simulations starting 
from monomeric peptides are further discussed in the course of our 
analyses to rule out co-assembly (see below), and then we describe 
DMD analyses on the effect of A16–22 fibrils on A40 aggregation 
(see below). Simulations performed on six monomers of A40 (Fig. 1C) 
showed that the initially unstructured peptides assemble and adopt 
a metastable oligomer structure by 104 s (Fig. 1C); this structure 
comprises antiparallel intramolecular  strands linked by disor-
dered regions assembled into antiparallel intermolecular sheets, 
with  strands stacked perpendicular to the long axis. During this 
oligomerization stage, the peptide conformation is similar to that ob-
served by Zheng et al. (17). As the simulation proceeds, this oligomer 
loses some -sheet content (t = 230 s; Fig. 1C). By the end of the 
simulation (621 s), peptides in oligomers undergo structural rear-
rangement from antiparallel -strand conformations to the parallel 
-sheet conformation observed for A40 fibrils (Fig. 1C) (37). Simu-
lations of the peptide mixtures did not show an accelerating effect 
of A16–22 monomers on the aggregation rate of A40 (see Fig. 3C 
and later). However, interactions between the two peptides were 
observed, consistent with the ESI-MS results in Fig. 3. From the 
DMD data, an energy contact map between the monomeric A16–22 
and A40 peptides was calculated (Fig. 3D). The contact map indi-
cated that A16–22, specifically residues 18 to 20 (VFF), interacts 
strongly with residues 19 to 21 and 32 to 35 of A40 (FFA and IGLM, 
respectively), consistent with experimental data previously reported, 
which indicate that KLVFF is a “self-recognition element” (27). Such 
an interaction between A16–22 and A40 oligomers, however, does 
not result in an acceleration of aggregation (Fig. 3C), implying that 
these mixed and low-abundance oligomers represent transient species 
that do not affect the rate of assembly (Fig. 3E).
A16–22 fibrils have a larger effect on the aggregation rate 
of A40 than A16–22 monomer
To determine whether rapidly formed A16–22 fibrils are the caus-
ative agents of the enhanced rate of A40 aggregation in the mixed 
samples (Fig. 1B), we assessed the effect of preformed A16–22 fibrils 
on A40 aggregation. These experiments (Fig. 4A) showed that the 
presence of A16–22 fibrils increases the rate of aggregation of A40 
Fig. 4. A16–22 fibrils increase the aggregation rate of A40 to a greater extent than A16–22 monomers. (A) Increased concentrations (% w/w) of A16–22 fibrils were 
added to A40 monomers (as shown in the key), and the aggregation rate was measured by ThT fluorescence. (B) Direct comparison of the effect of A16–22 monomers (i.e., 
taken straight from a DMSO stock) and A16–22 fibrils on A40 aggregation. (C) Effect of sonicating the A16–22 fibrils on the A40 aggregation rate shows little effect com-
pared with the data shown in (A) (see text for details). (D) Plots of the percent  sheet formed by A40 in the absence (blue) or presence of preformed two (black), three 
(red), or four (green) -sheet A16–22, determined using DMD, showing that an increased A16–22 fibril size increases the rate of A40 aggregation. (E) During co-aggregation 
experiments, both elongation and surface-catalyzed mechanisms can occur; each has a different effect on the rate of assembly of each peptide (the same notation is used 
as in Fig. 3E, with circles representing monomers, blocks representing fibrils, and A16–22 and A40 in red and blue, respectively). Adapted from (24).
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in a fibril concentration–dependent manner (Fig. 4A), and addition 
of A16–22 fibrils had a larger effect on the aggregation rate com-
pared with the addition of monomeric (i.e., taken straight from a 
DMSO stock) A16–22 (Fig. 4B). This suggests that aggregation is 
enhanced either by cross-seeding (i.e., by adding A40 directly to 
the ends of A16–22 fibrils) or by secondary nucleation of A40 on 
the A16–22 fibril surface (Fig. 4E). Sonication of fibrils fragments 
them, leading to a higher concentration of fibril ends. Hence, should 
elongation dominate the rate of fibril formation, sonication should 
markedly increase the rate of fibril growth. Comparison of the effects 
of unsonicated fibrils (fewer ends) with the same fibrils fragmented 
by sonication (Fig. 4C and see fig. S4 for TEM analyses) indicated 
that elongation was not dominant (Fig. 4C), because the average t1/2 
for sonicated fibrils (6.2 ± 1.0 hour) is similar to that of its unfrag-
mented counterpart (7.2 ± 0.7 hours). Together, the results demon-
strate that the presence of rapidly formed A16–22 fibrils enhances 
aggregation of A40 in peptide mixtures by secondary nucleation, 
despite the presence of small amounts of mixed oligomers (as demon-
strated by the ESI-IMS-MS experiments).
DMD simulations of the aggregation of six A40 peptides were 
also performed in the presence of preformed A16–22 fibrils of dif-
ferent sizes (two, three, and four  sheets) at an A40 concentration 
of 1 mM to model the dynamic process of the secondary nucleation 
event. The results (Fig. 4D) showed that the largest A16–22 fibril 
(i.e., four  sheets; green trace in Fig. 4D) led to the largest increase 
in the rate of -sheet formation by A40. Given that the presence of 
A16–22 monomers had no observable effect on A40 assembly (Fig. 3C), 
these simulations are thus qualitatively concordant with the experi-
mental findings that the fibrillar structure of A16–22 is the domi-
nant influence on the aggregation rate of A40. Such behavior is 
consistent with that observed for A40/42 co-aggregation for which a 
kinetic model has been established (24).
A40 and A16–22 form distinct homomolecular fibrils
The peptide composition of the final fibril structure(s) represents a 
further means to discern the difference between surface-catalyzed 
secondary nucleation and co-assembly exploiting fibril ends. A surface- 
catalyzed mechanism would most likely produce homomolecular fibrils 
of A40, as once they have formed on the A16–22 fibril surface, the 
A40 nuclei would dissociate and form pure A40 fibrils. In contrast, 
co-assembly involving fibril ends should result in mixed fibrils, in 
which A16–22 seeds are segmentally separated from fibril regions 
containing A40 monomers.
Negative-stain TEM images taken at the end of the aggregation 
reaction showed A40 fibrils with similar gross morphology when 
incubated in isolation or co-aggregated with A16–22 (Fig. 5, A and B). 
Similarly, quantitation of ThT fluorescence at the end-point of 
aggregation in mixed samples and quantitation of the same concen-
tration of A40 incubated alone were indistinguishable (fig. S3), 
supporting the hypothesis that homomolecular A40 fibrils are 
formed at the end of the assembly reaction. Last, PIC was used to 
explore whether homo- or heteromolecular fibrils had formed (Fig. 5C 
and Materials and Methods). To perform PIC experiments, a diazirine 
label was placed on F20 of A16–22 (A*16–22) (16). Control experi-
ments demonstrated that A*16–22 has a similar effect on the rate of 
A40 aggregation as its unmodified counterpart (fig. S3). PIC exper-
iments performed 5 min and 24 hours after initiating assembly 
failed to detect cross-links between A*16–22 and A40 (Fig. 5C, fig. S6, 
Fig. 5. A16–22and A40do not co-assemble during co-aggregation. Negative-stain TEM analysis of A40 incubated for 24 hours in the (A) absence or (B) presence of 
A16–22. Scale bars, 200 nm. (C) PIC of mixtures of diazirine-labeled A16–22 (A*16–22) and A40 incubated for 24 hours and then irradiated for 30 s. Only homomolecular 
A16–22 cross-links are observed, indicating that the fibrils are not copolymerized at the end of the reaction (the inset depicts the mechanism of PIC of the diazirine group. 
(D) DMD simulation snapshots of co-aggregation of A40 (blue) and A16–22 (red) indicate that separate homomolecular oligomers are formed at t = 202 s.
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and table S2). Instead, all identifiable cross-links were consistent with 
intermolecular/intramolecular A*16–22 or solvent adducts, as pre-
viously identified in A*16–22-containing fibrils by Preston et al. (16), 
indicating that co-assembly into fibrils either is very rare and can-
not be detected despite the sensitivity of ESI-MS or does not occur.
To provide a molecular image of co-assembly, we further ana-
lyzed the DMD simulations in which six A40 and six A16–22 
monomers were mixed and their aggregation behavior was moni-
tored versus time at Cpeptide = 5 mM (Fig. 5D). The simulations 
showed that in the early stages of assembly (t = 0.6 s), a mixture of 
monomeric and oligomeric A40 was present. As the simulation 
progressed (t = 57 s), all A40 peptides coalesced into one -sheet–rich 
oligomer, with A16–22 intercalated within the structure. Through-
out the simulation, monomeric A16–22 was observed to bind tran-
siently to other monomeric A16–22 peptides or the KLVFF motif of 
A40, in accordance with the data presented above. Last, at the end 
of the simulation (t = 202 s), the peptides form distinct oligomeric 
domains, with A40 and A16–22 forming separate sheets.
A40 oligomer dynamics on the surface of A16–22 fibrils
To obtain a molecular image of the process of secondary nucleation, 
we performed DMD simulations, in which six A40 monomers were 
mixed with preformed fibrils of A16–22 at CA40 = 5 mM (Fig. 6A). 
At the early stage of the simulation (t = 0.29 s), three A40 peptides 
were present in an oligomer: One A40 peptide was associated at the 
end of the fibril, and the remaining two A40 peptides were elongated 
across the fibril surface. At this stage (t = 0.29 s), the A40 peptides 
in the oligomer and on the surface were observed to adopt a pre-
dominantly random coil conformation with small amounts of -strand 
structure [note that an elongated monomeric structure was also ob-
served in simulations performed by Barz and Strodel (19) in exploring 
the secondary nucleation of A42 on the surface of A11–42]. The 
 sheets were next observed to act as templates for peptides present 
in a random coil conformation (1.93 s) and to pull them more fully 
to the fibril surface. Thus, as the simulation progressed, the A40 
peptides remaining in solution were recruited by those on the fibril 
surface. Once the oligomer became fully associated with the fibril 
surface, the amount of -sheet structure in the surface-associated 
oligomer increased (t = 7.7 s); antiparallel  strands formed via 
inter- and intramolecular hydrogen bonding, leading to sheet forma-
tion consistent with the early stages observed in the simulations per-
formed for A40 alone (t = 104 s; Fig. 1C). Last, the surface-associated 
A40 peptides were joined in an ordered oligomer (t = 29.0 and 77.7 s). 
Related “bind and reorganize” processes for secondary nucleation 
were observed in simulations performed by Schwierz et al. (38) using 
A9–40 as a model. As noted above, A40 peptides attached both to 
the lateral surface and to the end of the A16–22 fibril during the simu-
lation, with the A40 C-terminal region attaching more frequently to 
the lateral surface of the fibril than to the fibril ends at C = 5 mM 
(fig. S7). To assess the consistency of the results, we repeated the 
simulation three times; two of the three independent runs gave results 
similar to those described above, while for the final run, a greater 
number of associations to the fibril end were observed. Collectively, 
these results provide molecular images of surface-catalyzed nucleation, 
Fig. 6. A16–22fibrils catalyze A40assembly through secondary surface nucleation. (A) Simulation snapshots of the process by which A16–22 fibrils (red) increase the 
aggregation rate of A40 (blue) through a surface-catalyzed secondary nucleation. (B) A schematic description of the mechanism is also included, with A40 in blue and 
A16–22 in red.
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in which a random coil peptide is catalytically converted into a 
-sheet fibrillar structure on a fibril surface.
DISCUSSION
In this work, we used ESI-MS, PIC, and DMD to study the co- 
assembly mechanism of A16–22 and A40 into amyloid, demon-
strating the power of using integrated approaches to study structural 
determinants of molecular assembly processes. We show that mixed 
A16–22/A40 heteromeric oligomers form but that these are tran-
sient and lowly populated (~1%) and do not significantly affect the 
rate of aggregation. In contrast, A16–22 has a high propensity to 
self-associate into homomolecular fibrils, and these fibrils accelerate 
A40 assembly by monomer/oligomer interactions through secondary 
nucleation at the fibril surface. Recent modeling of amyloid assembly 
kinetics has revealed the importance of primary nucleation, secondary 
nucleation, and fibril elongation in fibril growth mechanisms (7, 10, 23). 
Notably, a kinetic model has been described for the co-aggregation of 
A40/42 (24). The experimental data presented here for co-aggregation 
of A16–22 and A40 qualitatively agree with this model, whereas our 
DMD simulations illustrate that while all primary/secondary nucle-
ation and elongation processes occur simultaneously, secondary 
nucleation is the dominant process in A40 fibril formation kinetics 
during co-assembly with A16–22, which is consistent with the find-
ings for the self-assembly mechanism of A40 observed previously 
(9, 10, 24). Moreover, A40 assembly intermediates on the surface of 
A16–22 fibrils resemble those formed spontaneously in solution for 
A40 alone, implying that the fibril surface catalyzes the assembly 
reaction without modifying the molecular mechanism, at least for 
the simulations performed here. Whether this holds for other se-
quences and co-assembly reactions will require further exploration 
(notably, which features of a fibril and the assembling monomer 
determine compatibility with secondary nucleation from a fibril 
surface).
Overall, the current study thus serves to emphasize the marked 
differences in aggregation behavior that are observed during co- 
aggregation compared to homomolecular self-assembly and under-
scores the need to use multiple methods to understand aggregation 
mechanisms in molecular detail. Significant current interest centers 
on characterizing distinct molecular steps leading to amyloid fibril 
formation, with secondary nucleation considered as playing a key 
role in causing toxicity (11, 39). Recently, kinetic analyses have been 
augmented by mapping the free-energy landscapes defining different 
microscopic phases in the aggregation pathway (11), providing insight 
to facilitate development of strategies that modulate the thermody-
namically distinct surface-monomer interactions characteristic of 
secondary nucleation. However, to design therapeutically useful 
modulators of amyloid aggregation requires that this understanding 
is complemented with structural insights of the molecular recogni-
tion between fibrils and monomers, set within the context of other 
interactions occurring during aggregation (e.g., monomer-nuclei 
interactions). We have shown here that A40 monomers and oligo-
mers dock onto the fibril surface, which catalyzes the assembly of 
antiparallel strand formation in close situ to the parent A16–22 fiber. 
Whether this is the end-point product or further reorganization is 
required to generate the final amyloid structure requires further study 
(longer simulation time). In this context, metastable amyloid struc-
tures have been observed for the Iowa mutant of A40 using solid- 
state NMR, in which antiparallel fibrils were observed as trapped 
intermediates in the assembly process to the final all-parallel fibril 
structure (40).
Together, the results demonstrate that kinetic analyses and theory 
together with MD provide a powerful arsenal and capability to visu-
alize secondary nucleation in structural and kinetic detail. Such 
approaches may allow informed targeting of this process to either 
prevent or accelerate secondary nucleation for therapeutic purposes 
and peptide material assembly. Co-aggregation adds an additional 
layer of complexity in understanding molecular assembly yet rep-
resents an opportunity to manipulate these supramolecular assem-
bly processes, as demonstrated here for the model system involving 
A16–22 and A40. Evidently, A40 shows a propensity to aggregate 
via secondary nucleation from its own fibril surface or that of other 
peptide sequences, as shown here for fibrils of A16–22. Hence, this 
work begins to address the molecular recognition events required 
for secondary nucleation to occur on a fibril surface and may in-
form strategies to modulate the aggregation of A40 under condi-
tions in which secondary nucleation dominates fibril growth.
MATERIALS AND METHODS
Synthesis of N-Fmoc TFMD-Phe and A peptides
N-Fmoc TFMD-Phe was synthesized using the method described 
by Smith et al. (41) and further minor changes in protecting group 
(scheme S1). A16–22, TAMRA-Ahx-A16–22, and A*16–22 were syn-
thesized via both automated and manual solid-phase peptide synthesis 
and dissolved into DMSO stock solutions before use (fig. S1). A40 
was synthesized recombinantly using the method of Walsh et al. 
(42) and modifications by Stewart et al. (43). To ensure that A40 
was monomeric before use, the peptide was purified by size exclu-
sion chromatography, lyophilized, and stored at −4°C (fig. S2).
ThT fluorescence assays
Samples were prepared in a 96-well nonbinding plate (Corning Costar 
3881, Corning Life Sciences, Amsterdam, the Netherlands) sealed 
with clear sealing film (BMG Labtech, Aylesbury, Bucks, UK) and 
were incubated in a FLUOstar OPTIMA plate reader (BMG Labtech, 
Aylesbury, Bucks, UK) for 20 hours at 37°C without agitation. Sam-
ples had a volume of 95 l containing 10 M ThT in 100 mM am-
monium bicarbonate (pH 7.4) and a final concentration of 1% (v/v) 
DMSO. For seeding experiments, A16–22 was incubated at 50 M 
for at least 24 hours in the same buffer as described above, with the 
presence of fibrils confirmed by TEM (described below). Before the 
assay, the fibrils were probe-sonicated for 5 s at 22% amplitude to 
generate “seeds.” The ThT experiments used excitation and emission 
filters of 430 and 485 nm. Each ThT experiment shown was repeated 
in independent assays on three different occasions, with the traces 
shown in this work being representative of all repeats.
Transmission electron microscopy
TEM images were taken at the end of each experiment by removing 
5 l from the necessary well and incubating this sample on carbon- 
formvar grids for 30 s before staining with 2% (w/v) uranyl acetate 
solution for an additional 30 s, as described by Preston et al. (27). 
Images were taken on a JEM-1400 (JEOL Ltd., Tokyo, Japan) or a 
Tecnai F12 TEM. Images were taken on a JEM-1400 (JEOL Ltd., 
Tokyo, Japan) or a Tecnai T12 (FEI, Hillsboro, OR, USA) TEM. Images 
were taken using either an ATM charge-coupled device (CCD) camera 
or a Gatan UltraScan 1000 XP (994) CCD camera (JEM-1400) or an 
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UltraScan 100XP (994) CCD camera (Tecnai F12). Once taken, images 
were processed using ImageJ [National Institutes of Health (NIH)].
General sedimentation protocol
Samples were taken at the desired time point and centrifuged (20 min, 
14,000g, 4°C). Each sample was then separated into pellet and super-
natant fractions, lyophilized overnight, and disaggregated in hexa-
fluoroisopropanol (HFIP) for at least 2 hours. HFIP was removed 
under a stream of N2, and the peptides were taken up in DMSO 
before analysis by high-resolution MS (Bruker HCT ion-trap MS).
Fluorescence quenching assays
Wild-type A16–22 was spiked with 5% (w/w) TAMRA-Ahx-A16–22 
and incubated either in isolation or at a 1:1 ratio with A40 (total 
peptide concentration, 40 M) in 100 mM ammonium bicarbonate 
buffer (pH 7.4) with a final concentration of 2% (v/v) DMSO. Samples 
were placed in quartz cuvettes and analyzed using a temperature- 
controlled fluorimeter at 37°C. Time points were taken every 30 s 
for the duration of the experiment, and TEM images (as described 
above) were taken at the end of each experiment to ensure the pres-
ence of fibrils. The TAMRA fluorophore was excited at 520 nm, and 
emission was recorded at 600 nm to reduce the inner filter effect.
ESI-IMS-MS analysis
All samples were prepared as described above and left to incubate at 
37°C without agitation for 5 min. A SYNAPT HDMS quadrupole 
time-of-flight MS (Micromass UK Ltd., Waters Corp., Manchester, 
UK), equipped with a TriVersa NanoMate (Advion Biosciences, 
Ithaca, NY, USA) automated nano-ESI interface, was used in this 
study. The instrument has a traveling-wave IMS device situated in 
between the quadrupole and the time-of-flight analyzers, as described 
in detail elsewhere. Samples were analyzed by positive ionization 
nano-ESI, with a capillary voltage of 1.4 kV and a nitrogen-nebulizing 
gas pressure of 0.8 psi. The following instrumental parameters were 
set: cone voltage, 60 V; source temperature, 60°C; backing pres-
sure, 4.7 mbar; ramped traveling speed, 7 to 20 V; traveling wave 
speed, 400 m s−1; IMS nitrogen gas flow, 20 ml min−1; IMS cell pres-
sure, 0.55 mbar. The mass/charge ratio (m/z) scale was calibrated 
using aq. CsI cluster ions. CCS measurements were estimated using 
a calibration obtained by analysis of denatured proteins (cytochrome c, 
ubiquitin, and alcohol dehydrogenase) and peptides (tryptic digests 
of alcohol dehydrogenase and cytochrome c), with known CCSs ob-
tained elsewhere from drift tube ion mobility measurements (15, 33). 
Data were processed using MassLynx v4.1 and Driftscope software 
supplied with a mass spectrometer.
Photo-induced covalent cross-linking
A 1:1 ratio of A16–22/A*16–22 or A*16–22/A40 (40 M total peptide 
concentration) in 100 mM ammonium bicarbonate buffer (pH 7.4) 
with a final concentration of 1% (v/v) DMSO was incubated in 
Eppendorf tubes for either 5 min or 24 hours. Samples were then 
irradiated for 30 s using a homebuilt light-emitting diode lamp at 
365 nm, then removed, lyophilized overnight, taken up in HFIP for 
at least 2 hours, and vortexed to ensure that any aggregates were 
disrupted. HFIP was then removed under a stream of N2, and the 
sample was resuspended in 50:50 (v/v) MeCN/H2O + 0.05% formic 
acid to a final concentration of ~40 M. Any cross-links were then 
analyzed using the method previously described and the ESI-IMS-MS 
system as described above (16).
DMD and PRIME20 force field
The simulation approach applied in this work is DMD, a fast alter-
native to traditional MD, in combination with the PRIME20 force 
field, a four-bead-per-residue coarse-grained protein model devel-
oped by the Hall group (44). In the PRIME20 model, each of the 20 
different amino acids contains three backbone spheres (NH, CH, 
and CO) and one side-chain sphere (R) with a distinct hard sphere 
diameter (effective van der Waals radius) and distinct side chain–
to–backbone distances (R-CH, R-NH, and R-CO). The backbone 
hydrogen bonding interaction is modeled as a directional square 
well potential. In the original PRIME20 force field, the potential 
function between any two side-chain beads on the 20 different amino 
acids (except glycine) is modeled as a single-well potential, contain-
ing 210 different square well widths and 19 different square well 
depths using the 5.5 Å heavy atom criteria. In this work, we follow 
Cheon’s approach to apply a double-square well potential instead of 
the single-square well for side chain–side chain interaction (45). All 
the other nonbonded interactions are modeled as hard sphere inter-
actions. A detailed description of the derivation of the geometric 
and energetic parameters of the PRIME20 model is given in our 
earlier work (46).
Simulation procedure
DMD/PRIME20 simulations were performed on the following sys-
tems: (i) six A40 monomeric peptides; (ii) six monomeric A40 
peptides with six monomeric A16–22 peptides; and (iii) six A40 
monomeric peptides in the presence of preformed two, three, and 
four -sheet A16–22 protofilaments. The two, three, and four -sheet 
A16–22 protofilaments contain 21, 42, and 71 peptides, respectively. 
Each simulation was performed at two different total peptide con-
centrations (1 and 5 mM). Similar seeding simulations were per-
formed in a previous work (45). The simulations were performed in 
the canonical ensemble (fixed number of particles, volume, and 
temperature). The reduced temperature was defined to be T* = kBT/HB, 
where the hydrogen bonding energy HB = 12.47 kJ/mol. The reduced 
temperature is related to real temperature by using the equation 
T/K = 2288.46T* − 115.79. The reduced temperature T* is chosen to 
be 0.20, which corresponds to a real temperature of 342 K. The system 
was maintained at a constant temperature by applying the Andersen 
thermostat. We performed 3 to 10 independent runs for each system.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/6/eaav8216/DC1
General materials and methods for organic synthesis
Synthesis of N-Fmoc–protected TFMD-Phe
General materials and methods for A16–22 solid-phase peptide synthesis
General materials and methods for HPLC purification
Analytical MS and HPLC data for synthetic peptides
General materials and methods for recombinant peptide synthesis
Additional characterization and analyses
CCS analysis of A40 in the presence and absence of A16–22
Scheme S1. Synthesis of TFMD-Phe.
Fig. S1. HRMS and analytical HPLC traces of A16–22 and its variants.
Fig. S2. SEC trace of A40 indicates that there is a single peak, and ESI-IMS-MS indicates that in 
the gas phase A40 is largely monomeric.
Fig. S3. Supplementary ThT data.
Fig. S4. Supplementary negative-stain TEM images.
Fig. S5. Analysis of the CCS values for A40 in the absence or presence of A16–22 over different 
IMS experiments.
Fig. S6. PIC analysis of 1:1 A*16–22/A40 at 5 min and 24 hours.
Fig. S7. Plot of the average number of hydrogen bonding and side chain–side chain.
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Table S1. The expected and observed m/z values for monomeric and oligomeric A40  
in isolation and in the presence of a 1:1 ratio of A16–22.
Table S2. Assignments of each of the major peaks observed in fig. S6A.
Data file S1. MD snapshots as pdb files Fig. 1 t = 0.
Data file S2. MD snapshots as pdb files Fig. 1 t = 104.
Data file S3. MD snapshots as pdb files Fig. 1 t = 230.
Data file S4. MD snapshots as pdb files Fig. 1 t = 621.
Data file S5. MD snapshots as pdb files Fig. 6 t = 0.29.
Data file S6. MD snapshots as pdb files Fig. 6 t = 1.16.
Data file S7. MD snapshots as pdb files Fig. 6 t = 1.93.
Data file S8. MD snapshots as pdb files Fig. 6 t = 7.7.
Data file S9. MD snapshots as pdb files Fig. 6 t = 29.
Data file S10. MD snapshots as pdb files Fig. 6 t = 77.7.
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